FDA grants Breakthrough Therapy Designation to ADCETRIS® (brentuximab vedotin)
Seattle Genetics announced the FDA has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas. November 15, 2018